Liraglutide formulations at pH 8.15 and pH 7.7 compared for bioequivalence in healthy subjects

Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, is a cornerstone treatment for type 2 diabetes and obesity, known for its glucose-dependent insulin secretion and appetite-suppressing effects. As drugs progress through development, formulation changes are common, often to improve stability, manufacturing efficiency, or patient experience. Ensuring that these new formulations maintain the same pharmacokinetic profile and therapeutic efficacy as previous versions is paramount for patient safety and consistent clinical outcomes. Bioequivalence studies are therefore critical, rigorously comparing different formulations to confirm they deliver the same amount of active drug to the bloodstream at the same rate, thereby addressing a key regulatory and clinical gap.

This European clinical trial was designed as a bioequivalence study, comparing two distinct liraglutide formulations in healthy subjects. The investigation focused on a phase 3a formulation of liraglutide at pH 8.15 (designated formulation 4) against an earlier formulation at pH 7.7 (designated formulation 3). The primary objective was to determine if these two formulations were bioequivalent, meaning they would exhibit comparable rates and extents of absorption. The abstract does not specify the dose, route of administration, frequency, duration of treatment, or the exact number of participants involved in the study.

The provided abstract snippet details the trial's aim and design but does not include any specific findings, results, or numerical data regarding the bioequivalence of the two liraglutide formulations. Consequently, no percentages, p-values, fold-changes, confidence intervals, or other statistical outcomes can be reported from this source. The study's conclusion regarding whether formulation 4 and formulation 3 were deemed bioequivalent is not available in this abstract.